PIC — Adjunctive Corticosteroids in Non-AIDS Severe PJP

1. Publication

• Title: Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial
• Acronym: PIC
• Year & Journal: The Lancet Respiratory Medicine, published online July 10, 2025 (print: 2025;13(9):800-808; erratum published Sept 2025)
• Citation: Lemiale V, Resche-Rigon M, Zerbib Y, et al. Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2025;13(9):800-808. doi:10.1016/S2213-2600(25)00125-0

2. Context & Rationale

Background: Pneumocystis jirovecii pneumonia (PJP) in HIV-negative immunocompromised patients carries hospital mortality of 30-50%. Adjunctive corticosteroids are established to improve outcomes in HIV-positive PJP patients, but their benefit in the growing HIV-negative immunocompromised population (increasing due to expanding immunosuppression trends in cancer and transplant medicine) had remained unestablished, motivating this dedicated trial.

Research Question/Hypothesis: In HIV-negative adults with acute respiratory failure due to PJP, does early adjunctive corticosteroid therapy (21-day methylprednisolone course) reduce 28-day mortality compared with placebo?

Why This Matters: As immunosuppression becomes more common (cancer therapies, solid organ transplant, autoimmune disease treatment), non-HIV PJP represents a growing population lacking the corticosteroid evidence base already established in HIV-positive patients — a genuine, previously unresolved clinical uncertainty.

3. Design & Methods

• Study Type: Multicenter, double-blind, randomized, placebo-controlled trial
• Setting & Centers: 27 hospitals, France
• Population:
• Inclusion: Adults ≥18y, acute respiratory failure with mild-to-severe hypoxemia, microbiologically documented PJP, anti-Pneumocystis treatment duration <7 days at enrollment
• Exclusions: HIV-positive status
• Intervention: Methylprednisolone IV — 30mg twice daily days 1-5, 30mg once daily days 6-10, 20mg once daily until day 21
• Comparator: Matched placebo (isotonic saline, 2-3mL syringes)
• Randomization: 1:1, web-based system, permutation blocks of fixed size unknown to local investigators, stratified by center and prior long-term corticosteroid treatment; 226 patients enrolled (111 placebo, 107 corticosteroid, based on trial text) over 7 years
• Blinding: Double-blind
• Statistical Power & Follow-Up: Primary outcome: 28-day mortality, intention-to-treat analysis. Secondary: 90-day mortality, intubation requirement, ventilator-free days at day 28.

4. Key Results

226 patients enrolled (ITT: 111 placebo, 107 corticosteroid, recruited over 7 years).

Key pattern: The primary (28-day mortality) endpoint was not met, but two important secondary outcomes (90-day mortality, intubation avoidance) were significantly improved — a notable divergence between the primary and key secondary endpoints.

5. Internal Validity Assessment

• Randomization & Allocation: Web-based randomization with permutation blocks of size unknown to local investigators, stratified by center and prior corticosteroid exposure — robust allocation concealment.
• Protocol Adherence & Separation: Matched placebo (identical-appearing saline syringes) ensures genuine blinding integrity; standardized 21-day corticosteroid taper protocol.
• Blinding & Detection Bias: Full double-blind design — a major methodological strength for this mortality/intubation-outcome trial, minimizing both performance and detection bias.
• Missing Data & Sensitivity Analyses: A published erratum (August 2025) corrected a statistical-analysis-section sentence regarding ventilator-free-days calculation — a methodological detail correction rather than a substantive results change.
• Overall Internal Validity Conclusion: Strong — double-blind, adequately powered (per prospective power analysis, per accompanying commentary), rigorously conducted trial; the divergence between a non-significant primary (28-day mortality) and significant secondary outcomes (90-day mortality, intubation) is a genuine, important finding pattern rather than a methodological flaw, though it does mean the trial technically did not meet its primary prespecified endpoint.

6. External Validity Assessment

• Population Representativeness: French, 27-hospital, HIV-negative immunocompromised PJP population with acute respiratory failure — directly representative of the growing non-HIV PJP population in modern immunosuppression-heavy medical practice (cancer, transplant, autoimmune disease treatment).
• Practice Context: Standard IV corticosteroid regimen, broadly deployable without special equipment.
• Overall External Validity Conclusion: Good — directly addresses a growing, previously understudied population (non-HIV immunocompromised PJP) with a simple, broadly available intervention.

7. Strengths & Limitations

Strengths:

• First large, double-blind, placebo-controlled RCT of adjunctive corticosteroids specifically in non-HIV PJP — filling a genuine evidence gap given the established HIV-positive PJP corticosteroid evidence base
• Rigorous double-blind design with matched placebo
• Significant benefit on two clinically important secondary outcomes (90-day mortality, intubation avoidance)
• Accompanying editorial specifically praises the trial's quality: "a superior trial using similar methods seems unlikely to be completed in the near future," reflecting the genuine difficulty of recruiting this population over 7 years

Limitations:

• Primary endpoint (28-day mortality) was not met — an important caveat despite the positive secondary findings
• Modest sample size (226 patients) reflecting the inherent challenge of recruiting this specific population
• Long recruitment period (7 years) may introduce practice-pattern heterogeneity
• Exact primary-outcome effect size/CI not accessible for this summary

8. Interpretation & Practice Impact

• Clinical Implications: While the primary 28-day mortality endpoint was not met, the significant reductions in 90-day mortality (HR 0.59) and intubation requirement (HR 0.36) provide a reasonably compelling case for considering adjunctive corticosteroids in non-HIV PJP with acute respiratory failure, extending the established HIV-positive PJP corticosteroid paradigm to this growing population.
• Mechanistic Coherence: Consistent with corticosteroids' established anti-inflammatory mechanism in PJP-associated respiratory failure (as in HIV-positive PJP), with the delayed emergence of mortality benefit at 90 (but not 28) days potentially reflecting a longer time course of benefit in this specific non-HIV population.
• Systems-Level Takeaway: Given the accompanying editorial's assessment that a superior trial is unlikely to be completed soon (reflecting genuine recruitment difficulty), this trial's secondary-outcome findings may need to inform practice despite the primary endpoint miss, pending any future confirmatory data.

9. Controversies & Subsequent Evidence

• Editorial Commentary: An accompanying Lancet Respiratory Medicine comment ("Adjunct corticosteroids for non-HIV infected patients with severe Pneumocystis jirovecii pneumonia") explicitly "applauds" the trial's quality while noting the practical difficulty (7-year recruitment across 27 hospitals) of ever completing a larger, more definitively powered confirmatory trial — suggesting this trial's secondary-outcome findings may represent the best available evidence for the foreseeable future.
• Guideline Integration: Adds to a prior body of observational evidence (systematic reviews/meta-analyses of observational studies) suggesting corticosteroid benefit in non-HIV PJP with respiratory failure; this RCT now provides the first randomized confirmation, albeit via secondary rather than primary endpoints.

10. Summary & Executive Takeaway

Summary: PIC, a double-blind, placebo-controlled RCT across 27 French hospitals, randomized 226 HIV-negative adults with PJP-related acute respiratory failure to a 21-day methylprednisolone taper or placebo. The primary endpoint (28-day mortality) was not significantly improved, but 90-day mortality (HR 0.59, 95% CI 0.37-0.93, P=0.022) and intubation requirement (HR 0.36, 95% CI 0.14-0.90, P=0.020) were both significantly reduced with corticosteroids.

Overall Takeaway: Although PIC did not meet its primary 28-day mortality endpoint, significant reductions in 90-day mortality and intubation requirement provide meaningful evidence supporting adjunctive corticosteroids in non-HIV PJP with respiratory failure — extending the established HIV-positive PJP corticosteroid paradigm to this growing, previously understudied immunocompromised population, in a trial an accompanying editorial suggests is unlikely to be surpassed in quality or feasibility any time soon.

11. Bibliography

• Ding L, Huang H, Wang H, He H. Adjunctive corticosteroids may be associated with better outcome for non-HIV pneumocystis pneumonia with respiratory failure: a systematic review and meta-analysis of observational studies. Ann Intensive Care. 2020;10(1):34.
• Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev.